Reshaping the Landscape of Cancer Drug Discovery and Development By Dr Paolo Paoletti The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades. In collaboration with… Read More
Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More
Molecular Diagnostics in Drug Development - The changing face of pharmaceutical discovery By Dr Berwyn Clarke Clinical drug development is moving into an era where high technology new diagnostics are key to the development of the majority of new drugs. Markers are now available that can be used as surrogate… Read More
Tools for Target Identification, Validation and Biomarker Discovery By Dr Paul Denny-Gouldson As automation in the drug discovery arena increases then so does the amount and complexity of the data. We discuss an emerging solution that now integrates various technologies to provide a scientific data intelligence tool giving scientists increasing… Read More
By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More
Serial vs Direct Dilution - Time to apply new thinking to IC50 determination and dose-response analysis? By Dr John Comley The serial dilution method is standard practice in the preparation of doseresponse series for IC50 determination. However, it is well recognised that inadequacies in the liquid handling or mixing technique… Read More
By Anthony Rosenberg Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue. There is a great deal of focus on discovering… Read More
India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity,… Read More
Kinase Screening and Profiling Products - Spoilt for choice By Dr John Comley The end user is spoilt for choice with the range of alternative offerings, methodologies and approaches currently available for kinase screening and profiling. Whereas wider coverage of the kinome was the principal focus of kinase profiling a… Read More
The Role of Microarray Technology in Pharmaceutical Development and Diagnostics By Richard Fisler The expectation that microarray technology will play a large role in shaping the future of pharmaceutical development and diagnostics has greatly increased due to new products and applications. Microarrays for gene expression have made a profound impact… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More
Monoclonals - The billion dollar molecules of the future By Dr Martin Wiles and Patrik Andreassen In 1975, two British scientists thought of creating a mouse antibody that could be replicated or 'cloned' to produce identical copies. Identical copies with identical modes of action had the potential to be a… Read More
Zebrafish: a versatile in vivo model for drug safety assessment Dr Wendy Alderton and Dr St phane Berghmans Safety pharmacology has become an integral part of non-clinical safety assessment for new chemical entities in the past two decades (1). The relative novelty of this discipline has granted it the flexibility… Read More
Confocal vs Widefield High Content Imaging By Dr John Comley A variety of new confocal hardware and software solutions have recently become available to support high content imaging. Most of the solutions have in common the potential of rejecting out-of-focus background fluorescence and of improving the signal to noise of… Read More
The Biomedical Ecosystem Delivering Better Health and Prosperity By Dr Peter B. Corr The overall message is simple: biomedical innovation and the public policies and new technologies that sustain and advance innovation are crucial to the future of biomedical science and the health and well being of our society. In… Read More
Medicinal Chemistry: Progress through innovation By Dr Terry Hart Medicinal chemistry is a specialised science that has evolved to encompass a broad range of disciplines concerned with the identification, synthesis and development of drug-like compounds for therapeutic use. It needs a wide range of expertise, developed through years of training,… Read More